ALPHA TAU MEDICAL LTD (DRTS) Stock Price, Forecast & Analysis
USA - NASDAQ:DRTS - IL0011839383 - Common Stock
DRTS Key Statistics, Chart & Performance
The current stock price of DRTS is 3.68 USD. In the past month the price decreased by -8.91%. In the past year, price increased by 58.62%.
DRTS Latest News, Press Relases and Analysis
DRTS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.28 | 219.56B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.58 | 202.41B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.88 | 143.74B | ||
| SYK | STRYKER CORP | 27.66 | 139.25B | ||
| IDXX | IDEXX LABORATORIES INC | 55.28 | 55.77B | ||
| BDX | BECTON DICKINSON AND CO | 13.26 | 54.81B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.47 | 50.50B | ||
| RMD | RESMED INC | 24.75 | 35.75B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.75 | 33.01B | ||
| PODD | INSULET CORP | 75.79 | 24.38B | ||
| DXCM | DEXCOM INC | 32.11 | 23.42B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.06 | 17.72B |
Related stock screener links
About DRTS
Company Profile
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The firm has one subsidiary Healthcare Capital Corp.
Company Info
ALPHA TAU MEDICAL LTD
Kiryat Hamada 5
JERUSALEM IL
Employees: 125
Phone: 97235774115
ALPHA TAU MEDICAL LTD / DRTS FAQ
What does DRTS do?
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The firm has one subsidiary Healthcare Capital Corp.
Can you provide the latest stock price for ALPHA TAU MEDICAL LTD?
The current stock price of DRTS is 3.68 USD.
Does DRTS stock pay dividends?
DRTS does not pay a dividend.
How is the ChartMill rating for ALPHA TAU MEDICAL LTD?
DRTS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for DRTS stock?
10 analysts have analysed DRTS and the average price target is 8.67 USD. This implies a price increase of 135.6% is expected in the next year compared to the current price of 3.68.
Can you provide the ownership details for DRTS stock?
You can find the ownership structure of ALPHA TAU MEDICAL LTD (DRTS) on the Ownership tab.
What is the Short Interest ratio of ALPHA TAU MEDICAL LTD (DRTS) stock?
The outstanding short interest for ALPHA TAU MEDICAL LTD (DRTS) is 0.16% of its float.
DRTS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to DRTS. When comparing the yearly performance of all stocks, DRTS is one of the better performing stocks in the market, outperforming 92% of all stocks.
DRTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DRTS. DRTS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
DRTS Financial Highlights
Over the last trailing twelve months DRTS reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS decreased by -20% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.73% | ||
| ROE | -40.64% | ||
| Debt/Equity | 0.07 |
DRTS Forecast & Estimates
10 analysts have analysed DRTS and the average price target is 8.67 USD. This implies a price increase of 135.6% is expected in the next year compared to the current price of 3.68.